It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Tuberculosis, an ancient, fatal airborne disease, has been treatable for decades with a cocktail of drugs. However, shoddy medical practices world-wide have enabled the bacteria to mutate and, in some cases, become all but untreatable
A catastrophic biological event could have devastating consequences. The U.S. government has efforts to provide detection and warning of biological threats. DHS’s BioWatch , which aims to detect certain pathogens in the air, is one such program. DHS has been pursuing a third generation of BioWatch technology (Gen - 3) to further enhance detection. GAO has published a series of reports on national biosurveillance efforts, including a report released today on DHS’s efforts to acquire Gen - 3.
the estimated date for full deployment has been delayed from fiscal year 2016 to fiscal year 2022 . T he 2009 life - cycle cost estimate — a poi nt estimate unadjusted for risk — was $2.1 billion . I n June 2011, DH S provided a risk - adjusted estimate at the 80 percent confidence level of $5.8 billion. Several steps remain before DHS can fully deploy Gen - 3 including additional performance testing, operational testing, and developing location specific deployment plans.
PositiveID Corporation (PSID), an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for rapid medical testing and diabetes management, today announced it has entered into a license agreement and a teaming agreement with The Boeing Company ("Boeing"), including a license fee to PositiveID of $2.5 million.
The license agreement provides Boeing the exclusive license to manufacture and sell PositiveID's M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector for the U.S. Department of Homeland Security's ("DHS") BioWatch Generation 3 opportunity, as well as other opportunities (government or commercial) that may arise in the North American market. Under the teaming agreement, PositiveID will retain exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing in the U.S. market. PositiveID will also retain the right to sell M-BAND units, reagents and assays in international markets.